Table 3.
Completed & ongoing clinical trials of AKT inhibitors for cancer therapy as of August 2024
| Drug | Company | Alternative names | Drug Class | Targets | Trial phase | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|---|
| MK-2206 | Merk & Co | MK-2206 hydrochloride | Allosteric | AKT 1/2/3 |
II I I II I |
|
| GSK2110183 | GlaxoSmithKline | Afuresertib | ATP-Competitive | AKT 1/2/3 | I/II | NCT01476137 |
| GSK2141795 | GlaxoSmithKline | Uprosertib | ATP-Competitive | AKT 1/2/3 |
I II I I/II II II II |
|
| AZD5363 | AstraZeneca | Capivasertib | ATP-Competitive | AKT 1/2/3 |
II Ib/II I II II II III |
|
| GDC-0068 | AbbVie | Ipatasertib | ATP-Competitive | AKT 1/2/3 |
I II II Ib II II I/Ib Ib/II II Ib II II II II II |